Clinical Intelligence

Quest, Genomic collaborate

Friday, July 15, 2011 10:25 AM

Quest Diagnostics and Genomic Vision announced a multi-year exclusive collaboration involving Genomic Vision's proprietary molecular combing genomic-analysis technology.

More... »

InSightec’s ExAblate shows promising results

Friday, July 15, 2011 10:23 AM

InSightec said 23 patients with organ-confined low-risk prostate cancer have been treated with its ExAblate(R) system in clinical trials, showing promising initial results.

More... »

Chimerix launches AdV HALT trial

Friday, July 15, 2011 10:21 AM

Chimerix, a biotechnology company, has begun patient dosing in the AdV HALT trial.  The FDA has granted CMX001 Fast Track designation status for the development program for this indication.

More... »

Sanofi, Regeneron announce trial results

Friday, July 15, 2011 10:19 AM

Sanofi and Regeneron Pharmaceuticals announced results from phase IIb trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor (IL-6R).

More... »

Arena posts phase I trial results

Wednesday, July 13, 2011 10:17 AM

Arena Pharmaceuticals has announced results from a phase I clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, or PAH.

More... »

Boston Scientific completes clinical trial enrollment

Wednesday, July 13, 2011 10:15 AM

Boston Scientific has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its Adapt Monorail Carotid Stent System in combination with its FilterWire EZ Embolic Protection System for treatment of carotid artery disease in patients at high risk for carotid surgery. 

More... »

Tarsa to advance clinical programs with $24.5M financing

Wednesday, July 13, 2011 10:02 AM

Tarsa Therapeutics reported progress in its two ongoing clinical development programs for its oral recombinant salmon calcitonin for the treatment and prevention of postmenopausal osteoporosis. Patient enrollment in the phase II osteoporosis prevention trial has been completed, and the full set of data from the phase III ORACAL trial has been accepted for an oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2011 annual meeting in September. Separately, Tarsa also said it has closed an additional financing round that raised a total of $24.5 million.

More... »

Micromet collaborates with Amgen

Tuesday, July 12, 2011 10:03 AM

Micromet has entered into a collaboration agreement with Amgen for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen.

More... »

Sunshine’s Adva-27a study results

Monday, July 11, 2011 12:33 PM

Sunshine Biopharma, a development stage pharmaceutical company, has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.  Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.  The results showed that Adva-27a is 16 times more effective at killing Multidrug Resistant Breast Cancer cells than Etoposide, the current commonly used drug.  Data generated by the study revealed that Adva-27a is unaffected by the molecular machinery which are responsible for making cancer cells resistant to drugs.

More... »

Generex publishes trial results

Monday, July 11, 2011 12:28 PM

Generex Biotechnology has published studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology.  Antigen Express, Generex’s subsidiary, has used this technology platform in the development of self-potentiating immunotherapeutic vaccines for cancer. 

More... »